Irene Ferrer

List of Publications by Year
in descending order

27	1,400	430874	526287
papers	citations	18	27
		h-index	g-index

29	29	29	2766
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Current Challenges in Cancer Treatment. Clinical Therapeutics, 2016, 38, 1551-1566.	2.5	549
2	RANK Induces Epithelialâ€"Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis. Cancer Research, 2012, 72, 2879-2888.	0.9	172
3	Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. Human Pathology, 2013, 44, 1973-1981.	2.0	87
4	MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e90524.	2.5	65
5	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. Stem Cell Reports, 2017, 8, 1392-1407.	4.8	62
6	PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis, 2007, 29, 491-499.	2.8	61
7	Characterization of the p53 Response to Oncogene-Induced Senescence. PLoS ONE, 2008, 3, e3230.	2.5	41
8	Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. Cell Cycle, 2011, 10, 2751-2762.	2.6	40
9	Spinophilin loss contributes to tumorigenesis in vivo. Cell Cycle, 2011, 10, 1948-1955.	2.6	31
10	Exploring the Gain of Function Contribution of AKT to Mammary Tumorigenesis in Mouse Models. PLoS ONE, 2010, 5, e9305.	2.5	28
11	Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. Journal of Clinical Investigation, 2019, 130, 612-624.	8.2	27
12	Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer. Disease Markers, 2016, 2016, 1-12.	1.3	26
13	The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction. Scientific Reports, 2018, 8, 2394.	3.3	26
14	Stromal signatures in endometrioid endometrial carcinomas. Modern Pathology, 2014, 27, 631-639.	5.5	23
15	Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1). Oncotarget, 2016, 7, 67033-67046.	1.8	23
16	The FOXO1-miR27 tandem regulates myometrial invasion in endometrioid endometrial adenocarcinoma. Human Pathology, 2014, 45, 942-951.	2.0	21
17	Downâ€regulation of *spinophilin* in lung tumours contributes to tumourigenesis. Journal of Pathology, 2011, 225, 73-82.	4.5	20
18	MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 195.	8.6	20

#	Article	IF	Citations
19	FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. EBioMedicine, 2020, 53, 102683.	6.1	15
20	Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications. Disease Markers, 2016, 2016, 1-14.	1.3	13
21	Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement. Clinical Lung Cancer, 2017, 18, 667-674.e1.	2.6	13
22	FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. Lung Cancer, 2019, 131, 112-121.	2.0	12
23	A patent review of FGFR4 selective inhibition in cancer (2007-2018). Expert Opinion on Therapeutic Patents, 2019, 29, 429-438.	5.0	10
24	Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer. Oncotarget, 2018, 9, 19945-19960.	1.8	6
25	Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry. Cells, 2019, 8, 806.	4.1	3
26	Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy. Journal of Clinical Medicine, 2022, 11, 1500.	2.4	3
27	Osimertinib in EGFR -mutant NSCLC: how to select patients and when to treat. Lancet Oncology, The, 2016, 17, 1622-1623.	10.7	2